A national study is seeking women in the U.S. to help determine the safest and best way to screen for breast cancer, and to improve on current guidelines. It’s being conducted at several sites across the country with the aim of enrolling 100,000 women, 40 to 74 years of age, who have not been diagnosed…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients
A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed or refractory multiple myeloma who received at least four prior therapies. This includes patients whose disease failed to respond to at least two proteasome inhibitors, two immunomodulatory agents, and a CD38 inhibitor,…
BioVaxys Advances Plans to Bring Vaccine to Clinic
BioVaxys is planning to request that its investigational vaccine for ovarian cancer, BVX-0918A, be approved for compassionate use in people with advanced ovarian cancer in Europe. The company also plans to file requests to U.S. and European regulatory health authorities requesting authorization to pursue clinical trials of BVX-0918A in the coming months. As part of…
Dosing Begins in Phase 1 Trial of CERC-007
Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating CERC-007 as a potential treatment for relapsed or refractory multiple myeloma. The trial (NCT04671251) intends to enroll up to 30 adult patients who received prior treatment with a proteasome inhibitor, an immunomodulatory agent, and a CD38 inhibitor. Recruitment is ongoing at four…
EU Approves Keytruda as First-line Treatment for Certain Colorectal Cancers
The European Commission has approved Keytruda (pembrolizumab) as a first-line therapy for adults with metastatic colorectal cancer whose tumors have certain genetic features, the company announced. The genetic features, according to a press release, include microsatellite instability-high (MSI-H) and deficient mismatch repair (dMMR), both good indicators that tumor cells have impaired DNA repair. These DNA repair deficiencies contribute…
Biological Clock Protein CRY-1 Eyed as Therapeutic Target
CRY-1, a regulator of our circadian clocks, contributes to disease spread and poor outcomes in prostate cancer patients by boosting DNA repair mechanisms that render cells more resistant to treatments, a study reveals. The findings support further investigation of CRY-1 as a therapeutic target, especially in prostate cancers that fail to respond to current therapies. The…
Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial
Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily pre-treated multiple myeloma patients in an ongoing Phase 1 trial. Findings to date from this open-label study (NCT03110822), which is being sponsored by Onco Therapeutics, showed that the combination not only elicited promising responses but was…
Bavencio Approved in EU as First-line Maintenance Therapy for Bladder Cancer
The European Commission (EC) has approved Bavencio (avelumab) as a first-line maintenance treatment for adults with advanced urothelial carcinoma, the most common form of bladder cancer, whose disease did not progress after platinum-based chemotherapy. This decision follows a positive recommendation from the Committee for Medicinal Products for Human Use, a branch of the European Medicines Agency. Bavencio…
Nonprofit Highlights Importance of Global Teamwork for World Cancer Day
In honor of World Cancer Day on Feb. 4, the Breast International Group (BIG) emphasized the importance of wide-scale cooperation in efforts to advance cancer research. “None of BIG’s achievements would be possible without the willingness to work together,” stated a press release highlighting some of the clinical trials that are supported by BIG, an…
Combining Imaging Methods May Reduce Need for Tumor Biopsies
Combining two imaging methods can provide a more accurate sampling of single tumors — like those found in ovarian cancer — thus allowing doctors to capture the diverse cancer cells in the tumor with fewer biopsies, a new study found. The study, “Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience…
EPI-7386 Combo Therapies Enter Trial for Certain mCRPC Patients
Essa Pharma has entered a clinical collaboration with Janssen to evaluate its small molecule inhibitor EPI-7386, in combination with either Erleada (apalutamide) or Zytiga (abiraterone acetate) plus prednisone, for patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the agreement, Janssen will conduct up to two Phase 1/2 clinical trials evaluating these combinations in…
$10M Gift to Open Myeloma Research Center at Ohio State
A new research center at Ohio State University (OSU) aims to speed work into the discovery and development of more effective treatments for those with multiple myeloma. The Riney Family Foundation Myeloma Center for Advanced Research Excellence (Myeloma CARE) is being established through a $10 million gift from the Paula and Rodger Riney Foundation to the…